Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie    ABBV

ABBVIE

(ABBV)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
06/11/2019 06/12/2019 06/13/2019 06/14/2019 06/17/2019 Date
78.17(c) 78.57(c) 78.95(c) 78.69(c) 78.65 Last
4 210 211 4 165 677 2 925 049 4 075 868 3 083 160 Volume
+1.59% +0.51% +0.48% -0.33% -0.05% Change
More quotes
Financials (USD)
Sales 2019 32 801 M
EBIT 2019 15 469 M
Net income 2019 10 672 M
Debt 2019 32 475 M
Yield 2019 5,51%
Sales 2020 34 729 M
EBIT 2020 16 317 M
Net income 2020 11 298 M
Debt 2020 28 277 M
Yield 2020 5,95%
P/E ratio 2019 10,63
P/E ratio 2020 9,15
EV / Sales2019 4,48x
EV / Sales2020 4,11x
Capitalization 114 B
More Financials
Company
AbbVie specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohnâ'Ts disease, thyroid disease, Parkinsonâ'Ts disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with... 
Sector
Pharmaceuticals
Calendar
06/17Presentation
More about the company
Surperformance© ratings of AbbVie
Trading Rating : Investor Rating :
More Ratings
Latest news on ABBVIE
06/14ABBVIE : New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arth..
AQ
06/13ABBVIE : New Long-Term Data from Upadacitinib Phase 3 Studies in Rheumatoid Arth..
AQ
06/11ABBVIE : New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRI..
PR
06/10ABBVIE : to Present at the Goldman Sachs Global Healthcare Conference
AQ
06/10ABBVIE : MAVIRET™ now listed on the Nova Scotia and Manitoba formularies
AQ
06/07ABBVIE : to Present at the Goldman Sachs Global Healthcare Conference
PR
06/06ABBVIE : Receives Positive Recommendation from the pan-Canadian Oncology Drug Re..
AQ
06/05ABBVIE : Presents Data from Venetoclax Chemotherapy-Free Combination Regimen for..
AQ
05/31ABBVIE : Presents Results from Several Studies and Clinical Trials Investigating..
AQ
05/30ABBVIE : MAVIRET™ now listed in New Brunswick
AQ
More news
Analyst Recommendations on ABBVIE
More recommendations
Sector news : Pharmaceuticals - NEC
02:48aBAYER : Studies Herbicide Shift As It Looks Beyond Roundup
DJ
02:35aASTRAZENECA : Study Shows Cancer Drug Calquence Increases Time Without Disease P..
DJ
06/15Drug Firms Sue Over Ad Rule -- WSJ
DJ
06/14Drugmakers Sue to Block Federal Rule Requiring Drug Prices in TV Ads
DJ
06/14BAYER : to Invest Billions in Weedkillers in Wake of Roundup Controversy--Update
DJ
More sector news : Pharmaceuticals - NEC
Chart ABBVIE
Duration : Period :
AbbVie Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABBVIE
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 17
Average target price 90,1 $
Spread / Average Target 16%
EPS Revisions
Managers
NameTitle
Richard A. Gonzalez Chairman & Chief Executive Officer
Michael E. Severino Vice Chairman & President
Azita Saleki-Gerhardt Senior Vice President-Operations
Robert A. Michael Chief Financial Officer & Senior Vice President
Carlos Alban Vice Chairman & Chief Commercial Officer
Sector and Competitors
1st jan.Capitalization (M$)
ABBVIE-14.64%111 910
JOHNSON & JOHNSON8.55%348 981
PFIZER-2.04%233 072
ROCHE HOLDING LTD.13.39%227 848
NOVARTIS20.35%220 893
MERCK AND COMPANY8.34%206 641